The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1621
ISSUE 1621
April 5, 2021
Issue 1621
- An EUA for Bamlanivimab and Etesevimab for COVID-19
- Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding
- Semaglutide (Ozempic) for Weight Loss
- Low-Dose Colchicine for Coronary Artery Disease
- In Brief: Hypertension with Erenumab (Aimovig)
- Ripretinib (Qinlock) for GIST (online only)
- COVID-19 Vaccine Comparison Chart (Archived) (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
An EUA for Bamlanivimab and Etesevimab for COVID-19
April 5, 2021 (Issue: 1621)
The FDA has issued an Emergency Use Authorization
(EUA) for Lilly's investigational monoclonal antibodies
bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016)
to be administered together for treatment of
mild to moderate COVID-19 in patients ≥12...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.